Exhibitors

Pharsight Corporation

Phoenix NLME - The Future of NLME Modeling

Integrated graphics, including lattice plots, q-q plots, conditional weighted residuals plots and more
Parametric, FO and FOCE algorithms, including a nonparametric method
User defined log-likelihood for user-specified models
Optional integration with Pharsight's PKS™ data management system
Parallelized NLME algorithms: The Intel® multicore platform is supported and NLME algorithms are parallelized for speed
Can be connected to your grid or cluster.
Graphical workflow engine integrates data preparation, modeling and model selection, and generation of high quality tables and figures

High productivity modeling and simulation platform

Mango Solutions

Mango Solutions are a data analysis company based in the UK. Operating globally we assist our customers in delivering high performance statistical and programming solutions to the pharmaceutical industry. These solutions are tailored to exact customer requirements to provide unique bespoke applications.

Founded in 2002 Mango have experience of all the major technologies used by the pharmaceutical industry and also have extensive domain expertise to assist customers in choosing the right technologies for their situation. This means that we have knowledge and experience that can be brought to your projects and allows a different perspective to be considered.

Mango provide their customers with training in technologies such as R and S-PLUS, statistical assistance, IT programming consultancy and support services. We have expertise in extending the use and abilities of technologies such as R and S-PLUS, SAS and Matlab. Mango value their independence from vendors - this ensures that when we suggest a certain technology the customer knows that it is because we consider this to be the best fit rather than what we get paid on. Mango's determination to provide customer satisfaction means that customers return to us time and time again.

In the Pharmacometrics arena Mango have worked with the biggest companies to provide modeling and simulation solutions that allow users to interact with data from applications such as NONMEM in an intuitive manner. Users are able to access wide libraries of functionality before exporting the resulting analyses and graphical output via production ready outputs.

Mango are proud to be sponsoring ACOP and are looking forward to meeting you on our stand to show you some of the work we have been involved with.

Insightful Corporation

Insightful Corporation (NASDAQ:IFUL) is a provider of predictive analytics and reporting solutions that give companies the knowledge to act™. Insightful platform products S-PLUS®, Insightful Miner™, S-PLUS® Server; allow companies to perform sophisticated statistical data analysis and create high-quality graphics and reports. Insightful Life Science Solutions are focused on specific application areas such as clinical data analysis/modeling, reporting, graphics, interactive clinical review, sequential/adaptive clinical trial design and safety data analysis. The company has been delivering high-ROI solutions to thousands of companies for more than 20 years. Headquartered in Seattle, Insightful has offices in New York, North Carolina, France, Switzerland, and the United Kingdom, with distributors around the world. For more information, visit www.insightful.com, email info@insightful.com or call 1-800-569-0123.

Simulations Plus, Inc.

42505 10th Street West
Lancaster, CA 93534
Tel: 661.723.7723
Fax: 661.723.5524
E-mail: info@simulations-plus.com
Web: www.simulations-plus.com

Company Profile:
Simulations Plus' advanced simulation and modeling software, used worldwide by most major pharmaceutical companies, includes: the "gold standard" GastroPlus™, which simulates absorption, pharmacokinetics, and pharmacodynamics for oral and IV dosage; DDDPlus™, a simulation of in vitro dissolution experiments; ADMET Predictor™, to generate predictions for pKa, human Peff, logP/logD, solubility, Vd, protein binding, BBB penetration, multiple toxicities, and Fa at multiple dose levels; ADMET Modeler™, integrated with ADMET Predictor, to quickly build high quality SAR models from your data; and ClassPharmer™, to perform powerful structure classifications, generate R-tables and SARs, visualize and browse large molecular libraries to learn from HTS and other data.

Metrum Institute & Metrum Research Group

Metrum Institute is a nonprofit organization dedicated to solving unmet needs in biomedical research through quantitative modeling and simulation. Our efforts include applied academic research, training, education, resource sharing, and research and development efforts focused on new open-source tools and methods. For more info visit: www.metruminstitute.org

Metrum Research Group provides contract services aimed at enhancing biomedical R&D through quantitative modeling and simulation. Our collaborations with the pharma/biotech industry are characterized by cutting-edge science, transfer of knowledge, quality deliverables and innovative, strategic application of modeling and simulation technologies. For more info visit: www.metrumrg.com

Aegis Technologies

Tools for Computational Biology at any Level

Physiologically-based pharmacokinetic modeling
Virtual tissues and organs
Disease simulation
Biochemical reaction network simulation
Classical compartmental PK/PD modeling

Complex problems in computational biology demand flexible, sophisticated tools

acslX is a software environment for modeling, simulation and analysis of complex nonlinear systems and processes. Regardless of the biological phenomena you need to model, acslX allows you to represent the complete nonlinear behavior of the system or process. acslX features a rich modeling language, and a wide range of robust algorithms for the numerical solution of ordinary differential equations, differential algebraic equations, and discrete event behavior. Models are compiled into executable binary code ensuring the fastest possible performance and support for extremely large or complex models.

There is no limitation on program size, number of equations, states or variables. So your models can represent large real-life systems with all of their complexities, and without impairing your ability to understand, use, describe, and present them to your colleagues.

A legacy of solving the most demanding mathematical problems

As the descendant of the ACSL family of modeling and simulation tools, originally developed in 1974 and now widely used for PBPK and PK/PD modeling, acslX supports both textual and graphical languages for specifying complex biological models, and a Matlab-like scripting language for specification of parameter estimation, sensitivity analysis, Monte-Carlo, or Markov-Chain Monte Carlo analyses. For computationally intensive problems, acslX includes support for cluster/grid computing. Data integration capabilities with Microsoft Excel and Access are provided, and a PBPK/PK/PD toolkit is also available which includes linear and nonlinear PBPK models of various organs, exposure models for inhalation, oral and dermal exposures, and a variety of PD dose response models.

End-to-end capabilities for modeling, simulation and analysis of biological systems and data

Develop models using both a rich, text-based simulation language and quick, intuitive graphical representations
Create reusable libraries of models with graphical simulation blocks
Create sophisticated scripts for controlling simulation runs and performing complex analyses using a Matlab-like scripting language
Perform calibration, validation and uncertainty analysis using the sophisticated parameter estimation, sensitivity analysis, Monte-Carlo analysis and Bayesian analysis capabilities of acslX
Facilitate data import and export with acslX's integration with MS Access and Excel
Speed model creation with the PBPK/PK/PD toolkit of pre-built simulation blocks, and an SBML import utility for automatically generating acslX models from SBML-based systems biology models
Employ cluster/grid computing resources for computationally intensive problems

An affordable, professional alternative to open source

Individual user prices for acslX start at $500. Corporate site licenses are available starting at $7500. Consulting and training are also available.

More information about acslX is available at www.acslX.com, 800-647-ACSL or info@acslX.com.

Simcyp

Simcyp is the leader in providing solutions for the population-based mechanistic in vitro-in vivo extrapolation (IVIVE) of pharmacokinetic properties.

The Simcyp Population-based ADME Simulator is an advanced platform for modeling and simulation of drug absorption, distribution, metabolism and elimination (ADME) in virtual populations using routinely generated in vitro data. This product is exclusively licensed to members of the Simcyp Consortium; currently comprising 9 of the top 10 pharmaceutical companies worldwide.

Simcyp also runs interactive workshops on the optimal use and interpretation of in vitro ADME data and offers consultancy services on a range of ADME and pharmacokinetics/pharmacodynamics (PK-PD) issues.

Nonlinear Mixed Effects Consortium (NLMEc)

Innovations in modelling and simulation systems interoperability

Software systems currently used for modelling and simulation are of a fragmented nature as only very limited support exists for sharing data and models between systems. This session will briefly provide some background into the activities and objectives of the NonLinear Mixed Effects Consortium (NLMEc), and how the NLMEc expects to progress towards an interoperability concept for modelling and simulation software.

NLMEc: Eli Lilly, GlaxoSmithKline, Novartis, Novo Nordisk, Pfizer, and Servier.

Contents:

NLME Consortium Proof of Concept
- Interoperability between existing software through a novel framework interchange
- The Need for standards development to achieve the interoperability of the proposed framework
Modelling & Simulation Markup Language (M&SML)
- Standards for system-to-system interchange of data, models and related metadata for population PK/PD analyses
- Integration of M&SML with CDISC standards
Upcoming consortium plans and activities